Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221812 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitors (CGMs) and Readmission Rates
A NA study, sponsored by University of Maryland, Baltimore.
- Not yet
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT07221812 is a NA study that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 120 participants.
The verdict
NCT07221812, a NA study, has not yet begun recruiting, sponsored by University of Maryland, Baltimore.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
Among the diffident groups of patients, those with chronic and severe medical conditions are more likely to be readmitted to the hospital. It is not surprising therefore that patients with diabetes have high readmission rates. Patients with diabetes have 40% higher re-hospitalization rates compared with those patients without diabetes, with 30-day readmission rates reported to range between 14% and 26%. It should be noted that almost 30% of the patients with diabetes are experiencing two or more hospital admissions per year, accounting for more than 50% of total hospitalizations and hospital health care costs. This research application will evaluate whether the initiation of Continuous Glucose Monitor (CGM) devices at the time of hospital discharge will lead to better glucose control and health outcomes compared to the use of "finger sticks" Point of Care (POC) following hospital discharge among patients with diabetes. This study will be a two arm (Real Time CGM vs POC) single center RCT at the Baltimore VA Medical Center. One hundred and twenty individuals will be recruited and randomly assigned (1:1) to either Real Time CGM or to POC following hospital discharge. All subjects will be followed from for 3 months post hospital discharge.
Interventions
- DEVICE Continuous Glucose Monitor
- OTHER Control Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-06-18 |
| Est. Completion | 2028-06-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221812
The ClinicalTrials.gov registry entry for NCT07221812 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Continuous Glucose Monitor is the first listed.
NCT07221812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07221812 about?
NCT07221812 is a clinical study titled "Continuous Glucose Monitors (CGMs) and Readmission Rates". Among the diffident groups of patients, those with chronic and severe medical conditions are more likely to be readmitted to the hospital. It is not surprising therefore that patients with diabetes have high readmission rates. Patients with diabetes have 40% higher re-hospitalization rates compared ...
What is the current status of trial NCT07221812?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2026-06-18. Estimated completion is 2028-06-17.
What interventions are being tested in trial NCT07221812?
The interventions under investigation include: Continuous Glucose Monitor (DEVICE), Control Group (OTHER).
Who is sponsoring clinical trial NCT07221812?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.